FiercePharma2d
Merck halts Gardasil shipments to China, withdraws $11B sales target as demand nosedives
The continued decline of Merck & Co.’s HPV vaccine Gardasil in China has come to a head as the New Jersey drug giant is ...
STAT2d
Merck’s earnings miss focused attention on Gardasil. The real issue is Keytruda
Merck on Tuesday missed earnings estimates, lowered its guidance for this year’s earnings, and withdrew a target for sales of ...
BioSpace2d
Merck’s Gardasil Woes Grow as China Trade War Heats Up
Merck reported a 2% decline in Gardasil sales, after reaching a peak of $8.9 billion in 2023. Now with shipments to China paused, the HPV vaccine faces significant headwinds going into 2025.
Merck beats estimates on fourth-quarter on earnings—but stock slides pre-market on tepid 2025 guidance
Merck ( MRK) reported fourth quarter and full year earnings Tuesday, in line with Wall Street estimates. The bad news: Its ...
Big Pharma, Bigger Bargain: Why Merck Stock Is Too Cheap To Ignore (Upgrade)
Financial writer recommends Merck & Co., Inc. as a strong healthcare stock despite recent challenges, citing strong potential ...
FiercePharma3d
Lawmakers urge RFK Jr. to answer to Gardasil litigation conflict-of-interest concerns ahead of confirmation vote
Before the Senate's confirmation vote on President Donald Trump’s pick for secretary of the Department of Health and Human ...
The Tokenist3d
Merck Reports Mixed Q4: Beats Revenue, Short on EPS Expectations
When compared against market expectations, Merck’s fourth-quarter results were a mixed bag. The company reported non-GAAP EPS ...
Merck Q4 2024 Earnings Preview: Headwinds ahead, but familiar strengths to persist
Merck (NYSE:MRK) is scheduled to announce Q4 earnings results on Tuesday, February 4th, before market open. Truist Securities ...